Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Targets Executives With Powerful Misdemeanor Strategy

This article was originally published in The Tan Sheet

Executive Summary

Executives could face virtually unbeatable government criminal prosecutions and prison sentences more frequently if FDA follows recently announced enforcement plans, industry attorneys warn

Related Content

FDA Expects STD Claims Enforcement To Deter Future Violations
J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
FDA, Trade Groups Team Up To Bolster Enforcement On Tainted Supplements
Misdemeanor Charges Drive FDA's Park Doctrine Enforcement
FDA's Executive Responsibility Policy Could Sweep Up Board Members
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
FDA Will Seek More Authority Over Manufacturing In Wake Of J&J Recalls
First GMP Warning Letter Reflects FDA's List Of Major Concerns
FDA Plays Misdemeanor Card In Adulterated Supplement Prosecution
FDA Agrees With GAO Recommendations To Give Prosecutions Higher Priority





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts